SR34006 Compared to Vitamin K Antagonist (VKA) in the Treatment of Pulmonary Embolism

Inclusion Criteria: * Confirmed acute symptomatic Pulmonary Embolism (PE) with or without concomitant Deep Vein Thrombosis (DVT) * Written informed consent Exclusion Criteria: * Legal lower age limitations (country specific) * Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of PE * Other indication for VKA than PE/DVT * More than 36 hours pre-randomization treatment with therapeutic dosages of (LMW)heparin or initiation of VKA treatment prior to randomization * Participation in another pharmacotherapeutic study within the prior 30 days * Creatinine clearance \<10 mL/min, severe hepatic disease, or bacterial endocarditis * Life expectancy \<3 months * Active bleeding or high risk for bleeding * Uncontrolled hypertension: systolic blood pressure \>180 mm Hg or diastolic blood pressure \>110 mm Hg * Pregnancy or childbearing potential without proper contraceptive measures or women who are breastfeeding * Any other contraindication listed in the labeling of warfarin, acenocoumarol, unfractionated heparin, enoxaparin, or tinzaparin